Peptide inhibition of acute lung injury in a novel two-hit rat model

Acute lung injury (ALI) often causes severe trauma that may progress to significant morbidity and mortality. ALI results from a combination of the underlying clinical condition of the patient (e.g., inflammation) with a secondary insult such as viral pneumonia or a blood transfusion. While the secondary insult may be variable, the rapidly progressive disease process leading to pulmonary failure is typically mediated by an overwhelming innate immunological or inflammatory reaction driven by excessive complement and neutrophil-mediated inflammatory responses. We recently developed a ‘two-hit’ ALI rat model mediated by lipopolysaccharide followed by transfusion of incompatible human erythrocytes resulting in complement activation, neutrophil-mediated ALI and free DNA in the blood indicative of neutrophil extracellular trap formation. The objective of this study was to evaluate the role of peptide inhibitor of complement C1 (RLS-0071), a classical complement pathway inhibitor and neutrophil modulator in this animal model. Adolescent male Wistar rats were infused with lipopolysaccharide followed by transfusion of incompatible erythrocytes in the presence or absence of RLS-0071. Blood was collected at various time points to assess complement C5a levels, free DNA and cytokines in isolated plasma. Four hours following erythrocyte transfusion, lung tissue was recovered and assayed for ALI by histology. Compared to animals not receiving RLS-0071, lungs of animals treated with a single dose of RLS-0071 showed significant reduction in ALI as well as reduced levels of C5a, free DNA and inflammatory cytokines in the blood. These results demonstrate that RLS-0071 can modulate neutrophil-mediated ALI in this novel rat model.

[1]  O. Arrieta,et al.  Radiation-induced lung injury: current evidence , 2021, BMC Pulmonary Medicine.

[2]  Choongho Lee,et al.  Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective , 2021, Archives of pharmacal research.

[3]  Sumit Ghosh,et al.  From virus to inflammation, how influenza promotes lung damage , 2020, Journal of leukocyte biology.

[4]  L. Gershwin,et al.  A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics , 2020, Clinical Reviews in Allergy & Immunology.

[5]  N. Schmidt,et al.  Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19 , 2020, Frontiers in Immunology.

[6]  John D Lambris,et al.  Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis , 2020, medRxiv.

[7]  N. Krishna,et al.  Inhibition of complement activation, myeloperoxidase, NET formation and oxidant activity by PIC1 peptide variants , 2019, PloS one.

[8]  C. E. van der Schoot,et al.  The Role of Complement in Transfusion-Related Acute Lung Injury , 2019, Transfusion Medicine Reviews.

[9]  J. Semple,et al.  The Pathogenic Involvement of Neutrophils in Acute Respiratory Distress Syndrome and Transfusion-Related Acute Lung Injury , 2018, Transfusion Medicine and Hemotherapy.

[10]  N. Krishna,et al.  Inhibition of Immune Complex Complement Activation and Neutrophil Extracellular Trap Formation by Peptide Inhibitor of Complement C1 , 2018, Front. Immunol..

[11]  N. Krishna,et al.  Peptide Inhibitor of Complement C1 (PIC1) demonstrates antioxidant activity via single electron transport (SET) and hydrogen atom transfer (HAT) , 2018, PloS one.

[12]  Nazita Yousefieh,et al.  Peptide Inhibitor of Complement C1 (PIC1) Inhibits Growth of Pathogenic Bacteria , 2019, International Journal of Peptide Research and Therapeutics.

[13]  N. Krishna,et al.  Inhibition of Myeloperoxidase Activity in Cystic Fibrosis Sputum by Peptide Inhibitor of Complement C1 (PIC1) , 2017, PloS one.

[14]  V. Janout,et al.  Past and Present ARDS Mortality Rates: A Systematic Review , 2017, Respiratory Care.

[15]  F. Lattanzio,et al.  Peptide inhibitor of complement C1 modulates acute intravascular hemolysis of mismatched red blood cells in rats , 2016, Transfusion.

[16]  N. Thielens,et al.  Peptide Inhibitor of Complement C1 (PIC1) Rapidly Inhibits Complement Activation after Intravascular Injection in Rats , 2015, PloS one.

[17]  F. Lattanzio,et al.  Complement inhibition significantly decreases red blood cell lysis in a rat model of acute intravascular hemolysis , 2014, Transfusion.

[18]  D. Wilkes,et al.  Complement system in lung disease. , 2014, American journal of respiratory cell and molecular biology.

[19]  M. Nicolls,et al.  Complement components as potential therapeutic targets for asthma treatment. , 2014, Respiratory medicine.

[20]  J. Ribeiro,et al.  Epidemiological and genetic characteristics associated with the severity of acute viral bronchiolitis by respiratory syncytial virus. , 2013, Jornal de pediatria.

[21]  Z. Werb,et al.  Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. , 2012, The Journal of clinical investigation.

[22]  J. Hartwig,et al.  Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. , 2011, Blood.

[23]  C. Silliman,et al.  Transfusion-related acute lung injury. , 2006, Blood reviews.

[24]  A. Paterson,et al.  The association of biologically active lipids with the development of transfusion‐related acute lung injury: a retrospective study , 1997, Transfusion.